Biliary iron excretion in rats following treatment with analogs of pyridoxal isonicotinoyl hydrazone

Blood

Volumn 91, Issue 11, 1998, Pages 4368-4372

  Bláha, Karel ^b   Cikrt, Miroslav ^b   Nerudová, Jana ^b   Fornusková, Helena ^b   Poňka, Přemysl ^a  

^a MCGILL UNIVERSITY   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CHELATING AGENT; DEFERIPRONE; DEFEROXAMINE; PYRIDOXAL 2 FUROYLHYDRAZONE; PYRIDOXAL 2 THIOPHENECARBOXYLHYDRAZONE; PYRIDOXAL 3 FLUOROBENZOYLHYDRAZONE; PYRIDOXAL 4 METHOXYBENZOYLHYDRAZONE; PYRIDOXAL BENZOYLHYDRAZONE; PYRIDOXAL ISONICOTINOYLHYDRAZONE; PYRIDOXAL ISONICOTINOYLHYDRAZONE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; ATOMIC ABSORPTION SPECTROMETRY; BILIARY EXCRETION; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; INTRAGASTRIC DRUG ADMINISTRATION; INTRAPERITONEAL DRUG ADMINISTRATION; IRON CHELATION; IRON KINETICS; IRON OVERLOAD; NONHUMAN; PRIORITY JOURNAL;

EID: 2642709214     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v91.11.4368.411k36_4368_4372     Document Type: Article

References (36)

1. Porter J, Huehns E, Hider R: The development of iron chelating drugs. Ballière's Clin Haematol 2:257, 1989
2. Hershko C: Iron chelators, in Brock JH, Halliday JW, Pippard MJ, Powell LW (eds): Iron Metabolism in Health and Disease. Philadelphia, PA, Saunders, 1994, p 391
3. Hoffbrand AV: Prospects for oral chelation therapy. J Lab Clin Med 123:492, 1994
4. Kontoghiorges GJ, Aldouri MA, Hoffbrand AV: Effective chelation of iron in β-thalassemia with the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one. BMJ 295:1509, 1987
5. Olivieri NF, Koren G, St Louis P, Freedman MH, McClelland RA, Templeton DM: Studies of the oral chelators 1,2-dimethyl-3-hydroxy-pyrid-4-one in thalassemia patients. Semin Hematol 27:101, 1990
6. Hoffbrand AV, Barlett AN, Veys PA, O'Connor NT, Kontoghiorghes GJ: Agranulocytosis and thrombocytopenia in patients with Blackfan-Diamond Anaemia during oral chelator trial. Lancet 2:457, 1989
7. Cunningham JM, Al-Refaie FN, Hunter AE, Sheppard LN, Hoffbrand AV: Differential toxicity of α-keto hydroxypyridine iron chelators and desferrioxamine to human haemopoietic precursors in vitro. Eur J Haematol 52:176, 1994
8. Al-Refaie FN, Wonke B, Hoffbrand AV: Deferiprone-associated myelotoxicity. Eur J Haematol 53:298, 1994
9. Al-Refaie FN, Hoffbrand AV: Oral iron-chelating therapy: The L1 experience. Ballière's Clin Haematol 7:941, 1994
10. Hoffbrand AV: Oral iron chelation. Semin Hematol 33:1, 1996
11. Olivieri NF, Brittenham GM: Iron chelation therapy and treatment of thalassemia. Blood 89:739, 1997
12. Hoffbrand AV, Al-Refaie F, Davis B, Siritanakatkul N, Jackson BFA, Cochrane J, Prescott E, Wonke B: Long-term trial of deferriprone in 51 transfusion-dependent iron overloaded patients. Blood 91:295, 1998
13. Olivieri NF, Brittenham GM: Final results of the randomized trial of deferiprone (L1) and deferoxamine (DFO). Blood 90:264a, 1997 (suppl 1)
14. Ponka P, Borova J, Neuwirt J, Fuchs O: Mobilization of iron from reticulocytes. FEBS Lett 97:317, 1979
15. Ponka P, Borova J, Neuwirt J, Fuchs O, Necas E: A study of intracellular iron metabolism using pyridoxal isonicotinoyl hydrazone and other synthetic chelating agents. Biochim Biophys Acta 586:278, 1979
16. Cikrt M, Ponka P, Necas E, Neuwirt J: Biliary iron excretion in rats following pyridoxal isonicotinoyl hydrazone. Br J Haematol 45:275, 1980
17. Hoy T, Humphreys J, Jacobs A, Williams A, Ponka P: Effective iron chelation following oral administration of an isoniazid-pyridoxal hydrazone. Br J Haematol 43:443, 1979
18. Hershko C, Avramovici-Grisaru S, Link G, Gelfand L, Sarel S: Mechanisms of in vivo chelation by pyridoxal isonicotinoyl hydrazone and other imino derivatives of pyridoxal. J Lab Clin Med 98:99, 1991
19. Johnson DR, Pippard MJ, Murphy TB, Rose NJ: An in vivo evaluation of iron-chelating drugs derived from pyridoxal and its analogues. J Pharmacol Exp Ther 221:399, 1982
20. Williams A, Hoy T, Pugh A, Jacobs A: Pyridoxal complexes as potential chelating agents for oral therapy in transfusional iron overload. J Pharm Pharmacol 34:730, 1982
21. Ponka P, Grady RW, Wilczynska A, Schulman HM: The effect of various chelating agents on the mobilization of iron from reticulocytes in the presence and absence of pyridoxal isonicotinoyl hydrazone. Biochim Biophys Acta 802:477, 1984
22. Baker E, Vitolo ML, Webb JM: Iron chelation by pyridoxal isonicotinoyl hydrazone and analogues in hepatocytes in culture. Biochem Pharmacol 34:3011, 1985
23. Webb J, Vitolo ML: Pyridoxal isonicotinoyl hydrazone (PIH), a promising new iron chelator, in Fucharoen S, Rowley PT, Paul NW (eds): Thalassemia: Pathophysiology and Management Part B, March of Dimes Birth Defects Foundation, Birth Defects Original Article Series (vol 23, number 5B). New York, NY, Liss, 1987, p 63
24. Ponka P, Richardson D, Baker E, Schulman HM, Edward JT: Effect of pyridoxal isonicotinoyl hydrazone and other hydrazones on iron release from macrophages, reticulocytes and hepatocytes. Biochem Biophys Acta 967:122, 1988
25. Sharma BK, Tavill AS, Louis LM, Varnes AW: Predominance of biliary iron chelates in iron-loaded rats in vivo during I.V. deferoxamine (DF) or pyridoxal isonicotinoyl hydrazone (PIH). Hepatology 8:1240, 1988
26. Sharma BK, Tavill AS, Louis LN, Wiessen E, Varnes AW: Enterai pyridoxal isonicotinoyl hydrazone (PIH) is an effective chelator in experimental iron overload by promotion of biliary iron excretion. Hepatology 10:573, 1989
27. Brittenham GM: Pyridoxal isonicotinoyl hydrazone: An effective iron-chelator after oral administration. Semin Hematol 27:112, 1990
28. Baker E, Richardson DR, Gross S, Ponka P: Evaluation of the iron chelation potential of pyridoxal, salicylaldehyde and 2-hydroxy-1-naphthylaldehyde using the hepatocyte in culture. Hepatology 15:492, 1992
29. Nerudova J, Blaha K, Jehlickova H, Cikrt M: Testing of acyl hydrazones in mobilization of iron. Proceedings of the Seventeenth Symposium on Xenobiochemistry, May 30-31, 1991, Abstract No 6, Hradec Kralove, Czech Republic
30. Edward JT, Gauthier M, Chubb FL, Ponka P: Synthesis of new acylhydrazones as iron-chelating compounds. J Chem Eng Data 33:538, 1988
31. 210Pb in the rat. Br J Ind Med 29:74, 1972
32. Östlund K: Studies on the metabolism of methyl mercury and dimethylmercury in mice. Acta Pharmacol Toxicol 27:31, 1969 (suppl 1)
33. Golenser J, Domb A, Teomin D, Tsafack A, Nisim O, Ponka P, Cabantchik ZI: The treatment of animal models of malaria with iron chelators by use of novel polymeric device for slow drug release. J Pharmacol Exp Ther 281:1127, 1997
34. Richardson D, Vitolo LW, Baker E, Webb J: Pyridoxal isonicotinoyl hydrazone and analogues. Study of their stability in acid, neutral and basic aqueous solutions by ultraviolet-visible spectrophotometry. Biol Met 2:69, 1989
35. Richardson DR, Hefter GT, May PM, Webb J, Baker E: Iron chelators of the pyridoxal isonicotinoyl hydrazone class III. Formation constants with calcium(II), magnesium(II) and zinc(II). Biol Met 2:161, 1989
36. Hershko C, Grady RW, Cerami A: Mechanism of iron chelation in the hypertransfused rat: Definition of the two alternative pathways of iron mobilization. J Lab Clin Med 92:144, 1978